oxidopamine has been researched along with Behavior Disorders in 9 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "5% potassium oxonate (an uricase inhibitor) to induce hyperuricemia." | 3.91 | Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease. ( Dohgu, S; Fukae, J; Kataoka, Y; Koga, M; Matsumoto, J; Nakashima, A; Takata, F; Tsuboi, Y; Yamauchi, A, 2019) |
| "Severity of 6-OHDA-induced Parkinsonism was assessed by conventional behavioural tests." | 1.43 | Pretreatment with potassium channel blockers of 4-aminopyridine and tetraethylammonium attenuates behavioural symptoms of Parkinsonism induced by intrastriatal injection of 6-hydroxydopamine; the role of lipid peroxidation. ( Alipour Heidari, M; Dargahi, T; Faraji, A; Fraidouni, N; Haghdoost-Yazdi, H; Mahmudi, M; Piri, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakashima, A | 1 |
| Yamauchi, A | 1 |
| Matsumoto, J | 1 |
| Dohgu, S | 1 |
| Takata, F | 1 |
| Koga, M | 1 |
| Fukae, J | 1 |
| Tsuboi, Y | 1 |
| Kataoka, Y | 1 |
| Petri, D | 1 |
| Pum, M | 1 |
| Vesper, J | 1 |
| Huston, JP | 1 |
| Schnitzler, A | 1 |
| Haghdoost-Yazdi, H | 1 |
| Piri, H | 1 |
| Faraji, A | 1 |
| Fraidouni, N | 1 |
| Dargahi, T | 1 |
| Mahmudi, M | 1 |
| Alipour Heidari, M | 1 |
| Kim, TW | 1 |
| Moon, Y | 1 |
| Kim, K | 1 |
| Lee, JE | 1 |
| Koh, HC | 1 |
| Rhyu, IJ | 1 |
| Kim, H | 1 |
| Sun, W | 1 |
| Sheline, CT | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Inden, M | 1 |
| Kitamura, Y | 1 |
| Takata, K | 1 |
| Yasui, H | 1 |
| Yoshimoto, K | 1 |
| Ashihara, E | 1 |
| Breese, GR | 1 |
| Knapp, DJ | 1 |
| Criswell, HE | 1 |
| Moy, SS | 1 |
| Papadeas, ST | 1 |
| Blake, BL | 1 |
| Cunningham, MG | 1 |
| Connor, CM | 1 |
| Zhang, K | 1 |
| Benes, FM | 1 |
| Pienaar, IS | 1 |
| Schallert, T | 1 |
| Russell, VA | 1 |
| Kellaway, LA | 1 |
| Carr, JA | 1 |
| Daniels, WM | 1 |
1 review available for oxidopamine and Behavior Disorders
| Article | Year |
|---|---|
The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles.
Topics: Age Factors; Animals; Animals, Newborn; Brain; Brain Chemistry; Disease Models, Animal; Dopamine; Ex | 2005 |
8 other studies available for oxidopamine and Behavior Disorders
| Article | Year |
|---|---|
Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Hyperuricemia; Male; Mental Disorde | 2019 |
GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Animals; Disease Models, Animal; Diz | 2013 |
Pretreatment with potassium channel blockers of 4-aminopyridine and tetraethylammonium attenuates behavioural symptoms of Parkinsonism induced by intrastriatal injection of 6-hydroxydopamine; the role of lipid peroxidation.
Topics: 4-Aminopyridine; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; D | 2016 |
Dissociation of progressive dopaminergic neuronal death and behavioral impairments by Bax deletion in a mouse model of Parkinson's diseases.
Topics: Animals; Apoptosis; Apoptosis Inducing Factor; Atrophy; bcl-2-Associated X Protein; Disease Models, | 2011 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Detoxification of 6-hydroxydopamine-induced dopaminergic neurodegeneration by 5,5-dimethyl-1-pyrroline N-oxide, a radical trapper, in hemiparkinsonian rats.
Topics: Animals; Antioxidants; Behavior, Animal; Cyclic N-Oxides; Disease Models, Animal; Dose-Response Rela | 2012 |
Diminished serotonergic innervation of adult medial prefrontal cortex after 6-OHDA lesions in the newborn rat.
Topics: Animals; Animals, Newborn; Cell Communication; Cell Differentiation; Denervation; Disease Models, An | 2005 |
Early pubertal female rats are more resistant than males to 6-hydroxydopamine neurotoxicity and behavioural deficits: a possible role for trophic factors.
Topics: Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, | 2007 |